$105M Fine Against GlaxoSmithKline is Just the Cost of Doing Business Posted on June 23, 2014 by Larry Bodine It is seen as the cost of doing business. It may be illegal, but is also highly profitable, so why stop? That seems to be the attitude of many pharmaceutical companies – and the latest proof of that comes in the form of a $105 million fine leveled against GlaxoSmithKline Plc.